Target ALS and AFTD Announce Groundbreaking Partnership to Spur Drug and Biomarker Development for ALS and FTD


Today, The Association for Frontotemporal Degeneration (AFTD) and Target ALS announced a groundbreaking partnership and call for proposals to identify treatments and biomarkers for FTD and ALS. These two devastating, progressive diseases are now understood to overlap in genetic causes and biological mechanisms.

At the center of our partnership is a $5 million multi-year grant-making initiative that will spur collaboration and form research consortia comprised of scientists from academia and the pharmaceutical/biotech industry. These consortia will work to discover, validate, and develop specific candidate drug targets or candidate biomarkers that may translate into new therapeutic strategies or validated biomarkers for ALS and FTD.

Click here for more information.

Stay Informed


Sign up now and stay on top of the latest with our newsletter, event alerts, and more…